About EryDel
EryDel is a company based in Milan (Italy) founded in 2007 by Giovanni Mambrini was acquired by Quince Therapeutics in July 2023. EryDel has raised $31.7 million across 3 funding rounds from investors including Quince Therapeutics, European Union and Genextra. EryDel offers products and services including eDSP and AIDE Platform. EryDel operates in a competitive market with competitors including Sirnaomics, Arcturus Therapeutics, ViAqua, PharmaJet and Vaxxas, among others.
- Headquarter Milan, Italy
- Founders Giovanni Mambrini
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quince Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.7 M (USD)
in 3 rounds
-
Latest Funding Round
$31.7 M (USD), Series B
Apr 24, 2018
-
Investors
Quince Therapeutics
& 5 more
-
Employee Count
Not available
-
Acquired by
Quince Therapeutics
(Jul 24, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EryDel
EryDel offers a comprehensive portfolio of products and services, including eDSP and AIDE Platform.
Encapsulated dexamethasone for treating Ataxia-Telangiectasia in patients.
Technology platform for encapsulating drugs into red blood cells.
Funding Insights of EryDel
EryDel has successfully raised a total of $31.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31.7 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EryDel
EryDel has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Quince Therapeutics, European Union and Genextra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A holding company focused on life science investments is operated.
|
Locked | Locked | Locked | |
|
VC firm investing in seed and early stage companies in Italy
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for EryDel
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EryDel
Investment portfolio details for EryDel
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EryDel
Detailed financials for EryDel
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Erydel Comparisons
Peer comparison for EryDel
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EryDel
EryDel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Arcturus Therapeutics, ViAqua, PharmaJet and Vaxxas, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| Locked | Locked | Locked |
RNAi drug delivery technology is developed for aquaculture disease prevention.
|
|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
Detailed competitors of EryDel
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Erydel
Complete news archive for EryDel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EryDel
EryDel was founded in 2007 and raised its 1st funding round 6 years after it was founded.
EryDel is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
EryDel is a funded company, having raised a total of $31.7M across 3 funding rounds to date.
EryDel was founded in 2007 in Milan, Italy, focusing on biotechnology and drug delivery innovations. Operations center on the proprietary red cell loader (RCL) device and erykit, which enable loading of small molecules, proteins, and enzymes into human red blood cells. Therapeutics in the pipeline include erdex, advanced to phase 3 clinical trials, and eetm, completed through phase 2.
EryDel's top competitors include Sirnaomics, Arcturus Therapeutics and PharmaJet.
EryDel offers eDSP and AIDE Platform.
EryDel has 6 investors. Key investors include Quince Therapeutics, European Union, Genextra, Innogest Capital, and Focus Gestioni SGR.